Pfizer's shares have experienced a significant decline of 56% from their peak in 2021, which is not surprising considering its critical role in the fight against COVID-19. The demand for its COVID-19 vaccine, Comirnaty, and treatment, Paxlovid, surged during the peak of the pandemic. However, as the coronavirus situation has improved, the company's sales dropped by 41% last year, leading to a decrease of over 70% in income compared to the previous year. Despite the substantial decline, the selling pressure on Pfizer's stock may have exceeded expectations. Currently, the stock is not only undervalued but also offers an attractive dividend yield of 6.2%. Moreover, the dividend is well-supported, having been raised consistently for the past 15 years.
Discovering the natural beauty of Guilin, with its stunning limestone karst hills, winding rivers, and picturesque landscapes that have inspired Chinese poets and artists for centuries.
In recent developments, the value of Bitcoin surged to around $64,000, leading many observers to believe that a bullish trend has officially begun. Market speculation revolves around pinpointing the exact moment this upward trajectory commenced, as Bitcoin has seen a 46% increase since the beginning of the year and a remarkable 139% surge over the past six months when compared to the U.S. dollar.
Plan B, the creator of the stock-to-flow (S2F) valuation model, suggests that Bitcoin's "accumulation phase has ended." Drawing on historical patterns, he proposes that we might witness "10 months of face-melting FOMO" (fear of missing out) in the near future.
This recent surge in Bitcoin's value and the optimistic outlook from industry experts indicate that market sentiment is favoring Bitcoin's continued upward trajectory. The potential for significant growth and increasing interest from investors may lead to a period of intense excitement and FOMO-driven activity in the coming months.